Nita K. Patel

1965 -

Nita K. Patel (born 1965) is an Indian-American vaccinologist who leads vaccine development at Novavax. She oversaw the development of the Novavax COVID-19 vaccine. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 27

Date

Title

Authors

2020-02-22

Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA

Nita K. Patel, Gale Smith
2020-08-06

First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine

Nita K. Patel, Gale Smith, Cheryl Keech
2020-09-02

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

James Logue, Nita K. Patel, Gale Smith, Cheryl Keech
2020-10-14

Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity

Nita K. Patel, Gale Smith
2020-10-20

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru, Gabriel Ozorowski, Aleksandar Antanasijevic, Deli Huang, Xiaoning Wang, Jonathan L Torres, Jolene K Diedrich, John Yates, David Nemazee, James C. Paulson, Greg Glenn, Andrew B Ward, Nita K. Patel, Gale Smith, Hannah L Turner
2020-10-23

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Nita K. Patel, Gale Smith
2020-11-04

Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

Nita K. Patel, Gale Smith
2019-02-07

Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein

Qinghua Wang, Nita K. Patel, Gale Smith
2019-10-01

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants

Nita K. Patel
2019-08-12

Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection

Nita K. Patel, Gale Smith
2019-10-23

2753. Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Airuses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Seasonal Influenza Vaccine

Nita K. Patel, Gale Smith
2018-10-30

Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge

Nita K. Patel, Gale Smith
2018-11

LB19. Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants

Nita K. Patel, Gale Smith
2017-08-18

Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes

Nita K. Patel, Gale Smith
2017-05-01

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

Qing Zhu, Jason S McLellan, Nicole L Kallewaard, Nancy D Ulbrandt, Catherine Svabek, Josephine M McAuliffe, Daniel Wrapp, Nita K. Patel, Andy Q Yuan, JoAnn A Suzich
2015-07-10

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

Syed Mohammad Moin, Vicente Mas, Concepcion Palomo, José A. Melero, Jason S McLellan, Barney S. Graham, Nita K. Patel, Nancy D Ulbrandt, Morgan S A Gilman, Ulrich Baxa, Stephanie C Kabeche
2015-04-01

Correction for Hao et al., Infection and propagation of human rhinovirus C in human airway epithelial cells

Nita K. Patel, Catherine Svabek
2013-09-30

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

Nita K. Patel
2013-10-01

Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays

Nita K. Patel
2011-01-05

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab

Nita K. Patel
2011-12-19

Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab

Nita K. Patel
2008-12-01

Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus

Nita K. Patel, Peter A Kiener
2007-02-20

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

Nita K. Patel, Peter A Kiener, Herren Wu
2006-08-01

Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo

Ab Osterhaus, Ron Fouchier, Nita K. Patel, Peter A Kiener
2005-07-01

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

Nita K. Patel, Peter A Kiener, Herren Wu
2004-07-27

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

Lawrence Corey, Luis Branco, David W Kimberlin, Nita K. Patel, Janet Englund, John P DeVincenzo
2002-11-01

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences

E. Sally Ward, Nita K. Patel, William F. Dall'Acqua, Peter A Kiener, Herren Wu

Human - wd:Q87989050

Welcome to Inventaire

the library of your friends and communities

learn more